[go: up one dir, main page]

PE20000467A1 - Derivado de indol util como inhibidor de serotonina - Google Patents

Derivado de indol util como inhibidor de serotonina

Info

Publication number
PE20000467A1
PE20000467A1 PE1999000381A PE00038199A PE20000467A1 PE 20000467 A1 PE20000467 A1 PE 20000467A1 PE 1999000381 A PE1999000381 A PE 1999000381A PE 00038199 A PE00038199 A PE 00038199A PE 20000467 A1 PE20000467 A1 PE 20000467A1
Authority
PE
Peru
Prior art keywords
alkyl
indole derivative
derivative useful
serotonin inhibitor
alcoxy
Prior art date
Application number
PE1999000381A
Other languages
English (en)
Inventor
Peter Thaddeus Gallagher
Martin Victor Miles
Colin William Smith
John Fairhurst
William Martin Owton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20000467A1 publication Critical patent/PE20000467A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE n ES 1-6; m ES 1-2; p ES 1-2; R1 Y R2 SON H, ALQUILO C1-C4, ALCOXI C1-C4, OH-ALQUILO C1-C4, HALO, FENILO OPCIONALMENTE SUSTITUIDO, FENIL-ALQUILO C1-C4, ENTRE OTROS; O R1 Y R2 FORMAN UN CICLOALQUILO C3-C6, >C=O, C=NOR`; R' ES H, ALQUILO C1-C4; R3, R4 Y R5 SON H, HALO, NITRO, ALQUILO C1-C4, ALCOXI C1-C4, CO-ALQUILO C1-C4, R'R''N-SO2-, -COOR', -CONR'R'', -NR'R'', ENTRE OTROS; R' Y R'' SON H, ALQUILO C1-C4; R6 Y R7 SON H, ALQUILO C1-C4; X ES O, S; EL FLUOR ESTA UNIDO EN LAS POSICIONES 6 o 7. EL COMPUESTO I TIENE AFINIDAD SELECTIVA PARA LOS RECEPTORES DE 5HT SIENDO UN MODULADOR SEROTONERGICO UTIL PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL
PE1999000381A 1998-05-13 1999-05-10 Derivado de indol util como inhibidor de serotonina PE20000467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9810886.3A GB9810886D0 (en) 1998-05-13 1998-05-13 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
PE20000467A1 true PE20000467A1 (es) 2000-06-05

Family

ID=10832426

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000381A PE20000467A1 (es) 1998-05-13 1999-05-10 Derivado de indol util como inhibidor de serotonina

Country Status (11)

Country Link
US (1) US6166040A (es)
EP (1) EP0963983A1 (es)
JP (1) JP2002514642A (es)
AR (1) AR018859A1 (es)
AU (1) AU3838499A (es)
CA (1) CA2330796A1 (es)
CO (1) CO5031250A1 (es)
GB (1) GB9810886D0 (es)
PE (1) PE20000467A1 (es)
SV (1) SV1999000059A (es)
WO (1) WO1999058525A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825413D0 (en) 1998-11-19 1999-01-13 Lilly Co Eli Pharmaceutical compounds
US6844338B2 (en) 2000-05-18 2005-01-18 Eli Lilly And Company Piperidyindoles as serotonin receptor ligands
GB2362381A (en) * 2000-05-18 2001-11-21 Lilly Co Eli Pharmaceutically active indolyl-piperidines
AR028685A1 (es) * 2000-06-14 2003-05-21 Lundbeck & Co As H Derivados de indol
DK1294710T3 (da) * 2000-06-14 2005-10-03 Lundbeck & Co As H Indolderivater, der er egnede til behandlingen af CNS-lidelser
GB2370270A (en) * 2000-12-20 2002-06-26 Lilly Co Eli Pharmaceutical compounds
DK1392697T3 (da) * 2001-03-14 2005-02-14 Wyeth Corp Antidepressive azaheterocyclylmethylderivater af 2,3-dihydro-1,4-dioxino[2.3-f]quinolin
SK12012003A3 (en) 2001-03-29 2004-10-05 Bristol Myers Squibb Co Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US6861434B2 (en) * 2001-04-26 2005-03-01 Wyeth Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
US6555560B2 (en) * 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
US6906206B2 (en) 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
CN100352820C (zh) * 2002-09-12 2007-12-05 惠氏公司 抗抑郁的杂环稠合的苯并二噁烷的氮杂环甲基衍生物
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
MX2007002033A (es) * 2004-08-19 2007-04-26 Vertex Pharma Moduladores de receptores muscarinicos.
EP1817036B1 (en) * 2004-11-29 2012-07-04 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
RU2008130094A (ru) * 2005-12-22 2010-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
KR20080094964A (ko) * 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
KR20080098070A (ko) * 2006-02-22 2008-11-06 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제로서의 스피로 축합된 피페리딘
CA2656183A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2660903A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021545A2 (en) * 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010540640A (ja) * 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン作用性レセプターのモジュレーター
KR20230117597A (ko) * 2020-12-07 2023-08-08 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 작용제로서의 3-시클릭아민-인돌 유도체
KR102509625B1 (ko) * 2022-03-25 2023-03-14 주식회사 메드팩토 TGF-β 저해제의 합성에 유용한 중간체 및 이를 이용한 TGF-β 저해제 제조방법
WO2025021120A1 (zh) * 2023-07-24 2025-01-30 上海翊石医药科技有限公司 一类5-ht2a受体激动剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981881A (en) * 1975-08-14 1976-09-21 E. R. Squibb & Sons, Inc. 2-[(4-Phenyl-tetrahydropyridinyl)alkyl]-1H-isoindole-1,3(2H)-diones
JP2860688B2 (ja) * 1990-03-14 1999-02-24 第一製薬株式会社 インドール誘導体
FR2675801A1 (fr) * 1991-04-24 1992-10-30 Rhone Poulenc Rorer Sa Piperidines, leur preparation et les medicaments les contenant.
SE9103752D0 (sv) * 1991-12-18 1991-12-18 Astra Ab New compounds
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
TW421649B (en) * 1995-01-31 2001-02-11 Janssen Pharmaceutica Nv 4-(1H-indol-1yl)-1-piperidinyl derivatives
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives

Also Published As

Publication number Publication date
SV1999000059A (es) 2000-07-04
US6166040A (en) 2000-12-26
JP2002514642A (ja) 2002-05-21
CO5031250A1 (es) 2001-04-27
AU3838499A (en) 1999-11-29
AR018859A1 (es) 2001-12-12
WO1999058525A1 (en) 1999-11-18
EP0963983A1 (en) 1999-12-15
CA2330796A1 (en) 1999-11-18
GB9810886D0 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
PE20000467A1 (es) Derivado de indol util como inhibidor de serotonina
PE20250114A1 (es) Compuestos indol sustituidos y metodos de uso de los mismos
CO4440628A1 (es) Derivados de pirimidina condensados con un anillo heteroci- clico
PE20020692A1 (es) Compuestos derivados de benzotiofeno y su procedimiento de obtencion
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2164758T3 (es) Derivados de morfolina sustituidos y su uso como agentes terapeuticos.
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
DK0923542T3 (da) Arylsubstituerede cycliske aminer som selektive dopamin-D3-ligander
PE20030292A1 (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gabaa
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
ECSP045379A (es) Derivados de [1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos y contra la obesidad
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
DK0465398T3 (da) Indolforbindelser
ES2113368T3 (es) Antagonistas de serotonina.
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
PE20001543A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion en terapeutica
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
PE20080126A1 (es) Metodos para tratar trastornos cognitivos y otros afines

Legal Events

Date Code Title Description
FC Refusal